Literature DB >> 24227635

Acute hemodynamic effects of a selective serotonin reuptake inhibitor in postural tachycardia syndrome: a randomized, crossover trial.

Philip L Mar1, Vidya Raj, Bonnie K Black, Italo Biaggioni, Cyndya A Shibao, Sachin Y Paranjape, William D Dupont, David Robertson, Satish R Raj.   

Abstract

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are often prescribed in patients with postural tachycardia syndrome (POTS), and act at synaptic terminals to increase monoamine neurotransmitters. We hypothesized that they act to increase blood pressure and attenuate reflex tachycardia, thereby improving symptoms. Acute hemodynamic profiles after SSRI administration in POTS patients have not previously been reported.
METHODS: Patients with POTS (n=39; F=37, 39 ±9 years) underwent a randomized crossover trial with sertraline 50mg and placebo. Heart rate, systolic, diastolic, and mean blood pressure were measured with the patient seated and standing for 10 min prior to drug or placebo administration, and then hourly for 4 h. The primary endpoint was standing heart rate at 4 h.
RESULTS: At 4 h, standing heart rate and systolic blood pressure were not significantly different between sertraline and placebo. Seated systolic (106±12 mmHg vs. 101±8 mmHg; p=0.041), diastolic (72±8 mmHg vs. 69±8 mmHg; p=0.022), and mean blood pressure (86±9 mmHg vs. 81±9 mmHg; p=0.007) were significantly higher after sertraline administration than placebo. At 4 h, symptoms were worse with sertraline than placebo.
CONCLUSIONS: Sertraline had a modest pressor effect in POTS patients, but this did not translate into a reduced heart rate or improved symptoms.

Entities:  

Keywords:  SSRI; blood pressure; heart rate; postural tachycardia syndrome; sertraline

Mesh:

Substances:

Year:  2013        PMID: 24227635      PMCID: PMC3956655          DOI: 10.1177/0269881113512911

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  30 in total

1.  Diurnal variability in orthostatic tachycardia: implications for the postural tachycardia syndrome.

Authors:  Jordan A Brewster; Emily M Garland; Italo Biaggioni; Bonnie K Black; John F Ling; Cyndya A Shibao; David Robertson; Satish R Raj
Journal:  Clin Sci (Lond)       Date:  2012-01       Impact factor: 6.124

2.  Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group.

Authors:  K A Yonkers; U Halbreich; E Freeman; C Brown; J Endicott; E Frank; B Parry; T Pearlstein; S Severino; A Stout; A Stone; W Harrison
Journal:  JAMA       Date:  1997-09-24       Impact factor: 56.272

3.  Neurocardiogenic syncope coexisting with postural orthostatic tachycardia syndrome in patients suffering from orthostatic intolerance: a combined form of autonomic dysfunction.

Authors:  Khalil Kanjwal; Mujeeb Sheikh; Beverly Karabin; Yousuf Kanjwal; Blair P Grubb
Journal:  Pacing Clin Electrophysiol       Date:  2011-01-05       Impact factor: 1.976

4.  Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.

Authors:  M H Kronig; J Apter; G Asnis; A Bystritsky; G Curtis; J Ferguson; R Landbloom; D Munjack; R Riesenberg; D Robinson; P Roy-Byrne; K Phillips; I J Du Pont
Journal:  J Clin Psychopharmacol       Date:  1999-04       Impact factor: 3.153

5.  Vascular perturbations in the chronic orthostatic intolerance of the postural orthostatic tachycardia syndrome.

Authors:  J M Stewart; A Weldon
Journal:  J Appl Physiol (1985)       Date:  2000-10

6.  Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents.

Authors:  B P Grubb; D Samoil; D Kosinski; K Kip; P Brewster
Journal:  J Am Coll Cardiol       Date:  1994-08       Impact factor: 24.094

7.  Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial.

Authors:  M B Keller; J H Kocsis; M E Thase; A J Gelenberg; A J Rush; L Koran; A Schatzberg; J Russell; R Hirschfeld; D Klein; J P McCullough; J A Fawcett; S Kornstein; L LaVange; W Harrison
Journal:  JAMA       Date:  1998-11-18       Impact factor: 56.272

8.  Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline.

Authors:  Andréia Zavaloni Scalco; Maria Urbana Pinto Brandão Rondon; Ivani Credidio Trombetta; Mateus Camaroti Laterza; João Batista Costa Carvalho Azul; Eleanor Maria Pullenayegum; Mônica Zavaloni Scalco; Fátima Helena Sert Kuniyoshi; Maurício Wajngarten; Carlos Eduardo Negrão; Francisco Lotufo-Neto
Journal:  J Hypertens       Date:  2009-12       Impact factor: 4.844

9.  Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome.

Authors:  Samuel T Coffin; Bonnie K Black; Italo Biaggioni; Sachin Y Paranjape; Carlos Orozco; Phillip W Black; William D Dupont; David Robertson; Satish R Raj
Journal:  Heart Rhythm       Date:  2012-05-03       Impact factor: 6.343

10.  Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain.

Authors:  D T Wong; F P Bymaster; L R Reid; D A Mayle; J H Krushinski; D W Robertson
Journal:  Neuropsychopharmacology       Date:  1993-06       Impact factor: 7.853

View more
  6 in total

Review 1.  Pediatric Disorders of Orthostatic Intolerance.

Authors:  Julian M Stewart; Jeffrey R Boris; Gisela Chelimsky; Phillip R Fischer; John E Fortunato; Blair P Grubb; Geoffrey L Heyer; Imad T Jarjour; Marvin S Medow; Mohammed T Numan; Paolo T Pianosi; Wolfgang Singer; Sally Tarbell; Thomas C Chelimsky
Journal:  Pediatrics       Date:  2017-12-08       Impact factor: 7.124

Review 2.  Postural Tachycardia Syndrome: Beyond Orthostatic Intolerance.

Authors:  Emily M Garland; Jorge E Celedonio; Satish R Raj
Journal:  Curr Neurol Neurosci Rep       Date:  2015-09       Impact factor: 5.081

3.  Effect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome.

Authors:  Emily M Garland; Alfredo Gamboa; Victor C Nwazue; Jorge E Celedonio; Sachin Y Paranjape; Bonnie K Black; Luis E Okamoto; Cyndya A Shibao; Italo Biaggioni; David Robertson; André Diedrich; William D Dupont; Satish R Raj
Journal:  J Am Coll Cardiol       Date:  2021-05-04       Impact factor: 24.094

Review 4.  Neuronal and hormonal perturbations in postural tachycardia syndrome.

Authors:  Philip L Mar; Satish R Raj
Journal:  Front Physiol       Date:  2014-06-16       Impact factor: 4.566

5.  Postural orthostatic tachycardia syndrome is associated with platelet storage pool deficiency.

Authors:  William T Gunning; Beverly L Karabin; Thomas M Blomquist; Blair P Grubb
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

Review 6.  Postural Orthostatic Tachycardia Syndrome (POTS): A critical assessment.

Authors:  Brian Olshansky; David Cannom; Artur Fedorowski; Julian Stewart; Christopher Gibbons; Richard Sutton; Win-Kuang Shen; James Muldowney; Tae Hwan Chung; Suzy Feigofsky; Hemal Nayak; Hugh Calkins; David G Benditt
Journal:  Prog Cardiovasc Dis       Date:  2020-03-25       Impact factor: 11.278

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.